Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2A6 | P11509 | 2/20 | 0.59 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.59 |
| ▸ | HTR2A | P28223 | 1/20 | 0.50 |
| ▸ | HTR2C | P28335 | 1/20 | 0.50 |
| ▸ | HTR2B | P41595 | 1/20 | 0.50 |
| ▸ | IDO1 | P14902 | 1/20 | 0.50 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.47 |
| ▸ | LMNA | P02545 | 1/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.45 |
| ▸ | PYCR1 | P32322 | 1/20 | 0.43 |
| ▸ | MC4R | P32245 | 1/20 | 0.43 |
| ▸ | MC5R | P33032 | 1/20 | 0.43 |
| ▸ | CA12 | O43570 | 1/20 | 0.43 |
| ▸ | CA1 | P00915 | 1/20 | 0.43 |
| ▸ | CA2 | P00918 | 1/20 | 0.43 |
| ▸ | CA9 | Q16790 | 1/20 | 0.43 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
| ▸ | CYP2E1 | P05181 | 1/20 | 0.42 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9456940 | 0.82 | LMNA (0.60) | CYP2A6CYP1A2HTR2AHTR2CHTR2B | |
| SCHEMBL1145596 | 0.79 | CYP1A2 (0.55) | CYP2A6CYP1A2HTR2AHTR2CHTR2B | |
| SCHEMBL8812214 | 0.78 | CYP1A2 (0.54) | CYP2A6CYP1A2HTR2AHTR2CHTR2B | |
| SCHEMBL19825525 | 0.78 | CYP1A2 (0.54) | CYP2A6CYP1A2HTR2AHTR2CHTR2B | |
| SCHEMBL5528354 | 0.78 | CYP1A2 (0.54) | CYP2A6CYP1A2HTR2AHTR2CHTR2B | |
| SCHEMBL24217769 | 0.78 | CYP1A2 (0.54) | CYP2A6CYP1A2HTR2AHTR2CHTR2B | |
| SCHEMBL10868840 | 0.77 | CYP1A2 (0.52) | CYP2A6CYP1A2HTR2AHTR2CHTR2B | |
| SCHEMBL31122366 | 0.77 | SMN1; SMN2 (0.55) | CYP2A6CYP1A2HTR2AHTR2CHTR2B | |
| SCHEMBL1127606 | 0.77 | SMN1; SMN2 (0.55) | CYP2A6CYP1A2HTR2AHTR2CHTR2B | |
| SCHEMBL5221578 | 0.76 | SIGMAR1 (0.59) | CYP2A6CYP1A2HTR2AHTR2CHTR2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 55 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070098994-A1 | Imaging member having sulfur-containing additive | XEROX CORPORATION (US) | 2007-05-03 | — | — | US | claimed |
| US-20070015755-A1 | NOVEL COMPOUNDS AND COMPOSITIONS AS PROTEASE INHIBITORS | AXYS PHARMACEUTICALS, INC. (US) | 2007-01-18 | — | — | US | claimed |
| EP-1452522-A2 | Novel compounds and compositions as protease inhibitors | AXYS PHARMACEUTICALS, INC. (US) | 2004-09-01 | — | — | EP | claimed |
| US-20040147745-A1 | Novel compounds and compositions as protease inhibitors | AXYS PHARMACEUTICALS, INC. (US) | 2004-07-29 | — | — | US | claimed |
| EP-1178958-B1 | N-CYANOMETHYL AMIDES AS PROTEASE INHIBITORS | AXYS PHARM INC (US) | 2004-02-18 | — | — | EP | claimed |
| US-20030096796-A1 | Novel compounds and compositions as protease inhibitors | AXYS PHARMACEUTICALS, INC. (US) | 2003-05-22 | — | — | US | claimed |
| JP-2002539191-A | — | — | 2002-11-19 | — | — | JP | claimed |
| EP-1178958-A2 | N-CYANOMETHYL AMIDES AS PROTEASE INHIBITORS | AXYS PHARMACEUTICALS, INC. (US) | 2002-02-13 | — | — | EP | claimed |
| WO-2000055125-A2 | N-CYANOMETHYL AMIDES AS PROTEASE INHIBITORS | AXYS PHARMACEUTICALS, INC. (US) | 2000-09-21 | — | — | WO | claimed |
| CN-112533934-B | Polyoxometallate compounds exhibiting bright emissions and methods of making same | 纳米2D材料有限公司 | 2024-07-19 | — | — | CN | disclosed |
| CN-111406233-B | Photosensitive resin composition, dry film resist and cured product thereof | 日本化药株式会社 | 2023-12-26 | — | — | CN | disclosed |
| EP-3500252-B1 | MODIFIED PEPTIDES FOR USE IN TREATING NEURODEGENERATIVE DISORDERS | NEURO BIO LTD (GB) | 2022-11-02 | — | — | EP | disclosed |
| CN-114502613-A | Curable composition, cured product, and method for forming cured product | 东京应化工业株式会社 | 2022-05-13 | — | — | CN | disclosed |
| US-20220119389-A1 | BERBAMINE DERIVATIVES AND METHODS OF USE THEREOF | CITY OF HOPE | 2022-04-21 | — | — | US | disclosed |
| US-6455502-B1 | Compounds and compositions as protease inhibitors | AXYS PHARMACEUTICALS, INC. | 2002-09-24 | — | — | US | disclosed |
| US-20020035102-A1 | Azetidine derivatives, their preparation and medicaments containing them | AVENTIS PHARMA S.A. (FR) | 2002-03-21 | — | — | US | disclosed |
| EP-1178958-A2 | N-CYANOMETHYL AMIDES AS PROTEASE INHIBITORS | AXYS PHARMACEUTICALS, INC. (US) | 2002-02-13 | — | — | EP | disclosed |
| EP-1112251-A1 | AZETIDINE DERIVATIVES, PREPARATION AND MEDICINES CONTAINING THEM | Aventis Pharma S.A. (FR) | 2001-07-04 | — | — | EP | disclosed |
| WO-2000055125-A2 | N-CYANOMETHYL AMIDES AS PROTEASE INHIBITORS | AXYS PHARMACEUTICALS, INC. (US) | 2000-09-21 | — | — | WO | disclosed |
| WO-2000015609-A1 | AZETIDINE DERIVATIVES, PREPARATION AND MEDICINES CONTAINING THEM | AVENTIS PHARMA S.A. (FR) | 2000-03-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030096796-A1 | Novel compounds and compositions as protease inhibitors | CTRL, SERPINB1, CPN1 | CYP2A6 1856/4885CYP1A2 2894/4885HTR2A 4434/4885 |
| US-20040147745-A1 | Novel compounds and compositions as protease inhibitors | CTRL, SERPINB1, CPN1 | CYP2A6 1856/4885CYP1A2 2894/4885HTR2A 4434/4885 |
| US-20070015755-A1 | NOVEL COMPOUNDS AND COMPOSITIONS AS PROTEASE INHIBITORS | CTRL, SERPINB1, CPN1 | CYP2A6 1856/4885CYP1A2 2894/4885HTR2A 4434/4885 |
| US-20220119389-A1 | BERBAMINE DERIVATIVES AND METHODS OF USE THEREOF | BHMT, HMBS, NNMT | CYP2A6 1002/4885CYP1A2 473/4885HTR2A 1668/4885 |
| US-20020035102-A1 | Azetidine derivatives, their preparation and medicaments containing them | CYP11B2, AZI2, CYP2C19 | CYP2A6 129/4885CYP1A2 8/4885HTR2A 960/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.